#USA #New York #Century Health #COPD #Tessel Biosciences

Collaborative Breakthrough in COPD Treatment

In a significant advancement within the field of respiratory health, Century Health has established a collaboration with Tessel Biosciences focused on utilizing artificial intelligence-curated real-world data to drive early drug development for Chronic Obstructive Pulmonary Disease (COPD). This strategic partnership aims to enhance understanding of various COPD patient subpopulations that remain underrepresented in clinical research and suboptimal in treatment responses.

Understanding COPD and Existing Challenges

COPD is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions and resulting in approximately 3.5 million deaths in just the year 2021. Despite extensive research over the past decades, certain subpopulations of COPD patients, especially those with specific characteristics like mucus obstruction or non-Type 2 inflammation, have yet to be adequately studied and treated. Consequently, these segments often experience lower efficacy from current treatment options.

Using AI to Bridge Knowledge Gaps

Recognizing this gap, Century Health has developed an advanced AI model capable of sifting through complex data often overlooked in traditional research formats, such as electronic health records and unstructured clinical notes. This powerful tool allows for a more nuanced analysis of COPD-related variables, far surpassing what claims data can reveal. With this partnership, Tessel Biosciences will leverage these insights to pinpoint key clinical traits and characteristics, enabling faster and more precise assessment of disease features relevant to drug development.

Tessel Biosciences: Innovating Therapies for the Underserved

Tessel Biosciences is known for its innovative approach to biotechnology, employing human organoids and machine learning to model chronic diseases. The company aims to address unmet needs in COPD treatment by focusing on patient segments that traditionally do not respond well to current therapies, particularly those who may be resistant to standard inhaled treatments or biologics targeting only Type 2 inflammation. Through access to real-world data, Tessel can better understand and predict the responses of these patients to emerging therapies.

Immediate Insights from Real-World Data

By utilizing Century Health’s meticulously curated datasets, Tessel can gain immediate insights into how underserviced patient populations respond to existing treatments. The technology also provides a more adaptable alternative to conventional registries that may take years to establish before they can serve as research tools. This real-time data integration is anticipated to catalyze important discoveries, expediting the drug development process for COPD treatments.

Remarks from Leadership

Vish Srivastava, CEO and Co-Founder of Century Health, stated, "This partnership illustrates how AI-curated real-world data can meaningfully inform early drug development. The data we need for much of this advancement already exists in electronic records." In response, Naren Tallapragada, CEO and Co-Founder of Tessel Biosciences, emphasized the importance of real-world evidence in their drug development strategy. "We want to understand how unmet need in the real world compares to reports from clinical trials and academic medical centers."

Future Directions and Signal of Hope

This alliance aligns closely with Tessel's mission of integrating human biology and data into predictive drug development processes. The company is already seeing momentum, recently receiving a substantial grant of up to $4.2 million from ARPA-H to support its pioneering work that combines organoids and AI.

As Century Health and Tessel Biosciences move forward with this groundbreaking initiative, the hope is that their work will lay the foundation for a new era of precision medicine in COPD, enabling targeted, effective therapies that resonate with the complex realities faced by patients today. Through innovative collaboration, these two organizations are set to redefine potential outcomes in the treatment of chronic inflammatory airways and positively impact countless lives.